TCL Archive SWOG Phase III Trial To Test Treatment For Inoperable, Locally Advanced NSCLC September 28, 2001
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive In Brief: House Appropriations Bill Marked Up, Lid Clamped On; Wells Named DCT Board Chairman July 6, 1984
